Drug intelligence / Profile preview

aminacrine

Development stage
Unknown
Modality
Small Molecules
Administration
Topical, Vaginal
01

Overview

Aminacrine is a small molecule antiseptic and anti-infective agent belonging to the acridine class of compounds. It is highly fluorescent and has been used clinically as a topical antiseptic for its slow-acting germicidal properties against bacteria and fungi[2][7]. Aminacrine acts primarily by intercalating into DNA, disrupting nucleic acid function, which underlies both its antimicrobial activity and its use as an experimental mutagen[2][8]. It has also been shown to inhibit the PI3K/AKT/mTOR pathway in tumor cells by downregulating the p110 gamma subunit of phosphoinositide 3-kinase (PI3K), impacting cell survival pathways including p53 and NF-kappaB signaling[6]. Its principal clinical uses have included treatment of vaginal infections such as moniliasis (candidiasis), trichomonal vaginitis, Haemophilus infections, tinea versicolor, mastitis, minor wounds/burns (often in combination with cetrimide), and as a prophylactic agent in gynecological procedures[5][7].

Other names
9-aminoacridineacridin-9-amineacridin9-amineacridin 9-amineaminacrine hydrochlorideAcramine Yellow
02

Targets

DNATOP2A (DNA topoisomerase II)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)

Beyond the preview

Go deeper on aminacrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aminacrine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call